LY171883 is primarily known for its role as a selective leukotriene D4 receptor antagonist. It has been studied extensively in the context of respiratory diseases, particularly asthma. By blocking the action of leukotriene D4, it helps reduce inflammation and bronchoconstriction in the airways, providing relief from asthma symptoms. Its application has also been explored in other inflammatory conditions where leukotrienes play a key role, such as allergic rhinitis and chronic obstructive pulmonary disease (COPD). Additionally, research has investigated its potential in treating conditions involving excessive leukotriene activity, such as certain types of dermatitis and inflammatory bowel disease. While it has shown promise in preclinical and clinical studies, its therapeutic use has been limited due to the development of more advanced leukotriene-modulating drugs. Nevertheless, it remains an important compound in the study of leukotriene pathways and their role in inflammation.